Phase II trial using romidepsin after gemcitabine, dexamethasone, and cisplatin therapy in elderly transplant-ineligible patients with relapsed/refractory peripheral T-cell lymphoma: Study protocol

Satoshi Yamasaki, Akiko Kada, Hirokazu Nagai, Isao Yoshida, Ilseung Choi, Akiko M. Saito, Hiromi Iwasaki

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

Romidepsin is an important therapeutic option for patients with peripheral T-cell lymphoma (PTCL). However, the timing of romidepsin administration remains controversial. Romidepsin was launched in Japan as a consolidation therapy agent after conventional salvage chemotherapy with gemcitabine, dexamethasone, and cisplatin (GDP). GDP therapy will be administered every 3 weeks. If complete response, partial response, or stable disease is confirmed after 2-4 GDP cycles, romidepsin will be administered every 4 weeks. The primary endpoint is a 2-year progression-free survival rate. Patients participating in this study and undergoing treatment can expect results similar to or better than those of conventional therapies.

Original languageEnglish
Pages (from-to)469-474
Number of pages6
JournalActa medica Okayama
Volume73
Issue number5
Publication statusPublished - 2019
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint

Dive into the research topics of 'Phase II trial using romidepsin after gemcitabine, dexamethasone, and cisplatin therapy in elderly transplant-ineligible patients with relapsed/refractory peripheral T-cell lymphoma: Study protocol'. Together they form a unique fingerprint.

Cite this